Knowledge Insight: USP7 – A Multifunctional Deubiquitinase Driving Disease Pathogenesis and Targeted Therapy

Published by ANT BIO PTE. LTD.

1. Core Concepts

USP7 (also known as HAUSP) is a pivotal member of the ubiquitin‑specific protease (USP) deubiquitinase family. encoded at chromosome 16p13.2, this 128 kDa protein comprises an N‑terminal TRAF domain, a central catalytic domain, and C‑terminal UBL domains. By cleaving K48/K63 ubiquitin chains, USP7 governs protein stability, DNA repair, epigenetic regulation, and immune signaling, positioning it as a master regulator of cell fate and disease.

2. Research Frontiers

• Structural basis of USP7 substrate recognition and catalytic regulation
• Dual oncogenic / tumor‑suppressive roles in cancer
• USP7 in neurodegeneration, viral infection, and immune disorders
• Next‑generation USP7 inhibitors, allosteric modulators, and PROTACs
• Biomarker development for patient stratification in targeted therapy

3. Research Significance

USP7 is tightly linked to cancer, neurodegeneration, autoimmunity, and viral pathogenesis. Its ability to modulate the p53/MDM2 axis, DNA repair, and epigenetic modifiers makes it a high‑value therapeutic target. Specific, validated research tools are essential to dissect USP7 function, validate disease mechanisms, and accelerate drug discovery.

4. Key Mechanisms & Research Applications

4.1 Structure and Regulation

• TRAF domain: Mediates substrate recognition (P/AxxS motif)
• Catalytic triad (Cys‑His‑Asp): Drives deubiquitination activity
• UBL domains: Regulate localization, stability, and enzymatic activity
• Regulation: self‑deubiquitination, phosphorylation, cofactor binding (GMPS, WDR20)

4.2 Substrate Network and Signaling

USP7 controls a broad network of substrates:

• Tumor suppressors: p53, PTEN, FOXO4
• Oncogenes: MDM2, N‑Myc, c‑Myc, β‑catenin
• DNA repair: Claspin, CHK1, ATR‑CHK1 axis
• Epigenetics: EZH2, DNMT1
• Immunity: TRAF6, IKKγ, PD‑L1

4.3 Dual Role in Cancer

• Oncogenic: Overexpressed in many cancers; stabilizes MDM2 to inhibit p53; drives cancer stemness and drug resistance
• Tumor‑suppressive: Stabilizes p53, PTEN, and genome‑stability proteins
• Context dependency determines functional outcome

4.4 Roles in Other Diseases

• Neurodegeneration: Regulates α‑synuclein, tau, and mutant huntingtin
• Viral infection: Hijacked by EBV, HPV, HSV‑1 for immune evasion
• Autoimmunity: Controls Treg function and inflammatory signaling
• Metabolism & cardiovascular: Modulates insulin signaling and vascular remodeling

4.5 Targeted Therapy

• Inhibitors: FT671, P5091, ALM‑271 (preclinical/clinical stages)
• Strategies: catalytic inhibition, allosteric modulation, PROTACs, combination immunotherapy
• Challenges: on‑target toxicity, context‑dependent efficacy, resistance

[Image Position: USP7 Signaling Pathways and Therapeutic Intervention Map]

5. Research Tools Empowered by ANT BIO PTE. LTD.

ANT BIO PTE. LTD. provides high‑performance reagents to accelerate USP7 research, including highly specific antibodies, activity assays, and recombinant proteins.

Core Product Advantages

表格

Key Application Scenarios

表格

6. Brand Mission

ANT BIO PTE. LTD. is a premium provider of life science reagents, offering high‑performance antibodies, recombinant proteins, detection kits, and general laboratory reagents. We operate three specialized sub‑brands: Absin (general reagents & kits), Starter (antibodies), and UA (recombinant proteins), delivering integrated solutions to advance global research in deubiquitination, disease mechanisms, and targeted therapy.

7. Related Product List

9. Brand Promotion Copy

ANT BIO PTE. LTD. – Empowering Scientific Breakthroughs

At ANTBIO, we are committed to advancing life science research through high-quality, reliable reagents and comprehensive solutions. Our specialized sub-brands (Absin, Starter, UA) cover a full spectrum of research needs, from general reagents and kits to antibodies and recombinant proteins. With a focus on innovation, quality, and customer-centricity, we strive to be your trusted partner in unlocking scientific mysteries and driving medical progress. Explore our product portfolio today and elevate your research to new heights.